STOCK TITAN

Windtree Therapeutics, Inc. - WINT STOCK NEWS

Welcome to our dedicated page for Windtree Therapeutics news (Ticker: WINT), a resource for investors and traders seeking the latest updates and insights on Windtree Therapeutics stock.

Windtree Therapeutics, Inc. (NASDAQ: WINT) is a pioneering biotechnology company specializing in the development of innovative therapies for critical cardiovascular and respiratory conditions. The company's advanced research and proprietary technologies aim to address significant unmet medical needs, offering hope to patients and their families.

At the core of Windtree's portfolio is its KL4 surfactant technology, a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant. This technology is being developed for noninvasive administration via aerosolization, with a primary focus on treating Respiratory Distress Syndrome (RDS) in premature infants. The potential of this technology extends to various other respiratory diseases, promising new therapeutic avenues where few or no approved treatments exist.

In the cardiovascular domain, Windtree is advancing istaroxime, a Phase 2 candidate exhibiting unique dual mechanisms that enhance both systolic and diastolic cardiac functions. Istaroxime targets acute heart failure and cardiogenic shock, conditions with high mortality and limited treatment options. Recent collaborations, including a significant license agreement with Lee's Pharmaceutical, aim to develop and commercialize istaroxime in Greater China, reflecting its global potential.

Windtree is also exploring preclinical SERCA2a activators for heart failure, aiming to develop both intravenous and oral formulations to treat acute and chronic heart failure, respectively. Additionally, the company is advancing rostafuroxin, targeting hypertension in patients with specific genetic markers, and a preclinical atypical protein kinase C iota (aPKCi) inhibitor, for potential oncology applications.

Financially, Windtree's strategic licensing and partnerships, such as the recent agreement with Deerfield Management to retire a $15 million liability, have strengthened its balance sheet. The company is strategically positioned to advance its late-stage clinical programs while optimizing its financial resources to support ongoing and future endeavors.

Windtree's commitment to scientific innovation and strategic collaborations is poised to transform treatment paradigms in cardiovascular and respiratory care, with a robust pipeline that holds significant promise for the future.

Rhea-AI Summary

Windtree Therapeutics (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on July 13, 2021, at 11:00 am ET. The presentation will cover the company's innovative therapies for acute cardiovascular and pulmonary disorders. Windtree is developing istaroxime for acute heart failure and AEROSURF® for respiratory distress in premature infants. A replay will be available on their investor page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.29%
Tags
conferences
-
Rhea-AI Summary

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced the appointment of Diane Carman as Senior Vice President and General Counsel, effective July 1, 2021. Ms. Carman, with over 20 years of experience in the biotech sector, has a proven track record in legal compliance, corporate governance, and M&A. She previously served as General Counsel for various companies, including Vitara Biomedical. Her appointment is expected to bolster Windtree's legal framework as it advances late-stage interventions for acute cardiovascular and pulmonary disorders. Ms. Carman received stock options to purchase 150,000 shares as part of her inducement to join the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.87%
Tags
management
-
Rhea-AI Summary

Windtree Therapeutics (WINT) reported Q1 2021 results, highlighting an operating loss of $9.1 million, up from $6.7 million in Q1 2020. Research and development expenses increased to $4.4 million, driven by clinical development for istaroxime. The company raised approximately $30 million in equity financing, netting $27.4 million. Key updates include expanding a Phase 2 clinical study for istaroxime and dosing the first patient in a study of lucinactant for COVID-19 related acute lung injury. Cash and equivalents stood at $38.5 million as of March 31, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.15%
Tags
Rhea-AI Summary

Windtree Therapeutics (NasdaqCM: WINT) announced the filing of a Track One prioritized patent application with the USPTO for istaroxime. This expedited process is expected to yield examination results within one year, compared to the usual three years. Istaroxime, the company's lead asset, is under development for early cardiogenic shock and acute heart failure (AHF). The company is conducting an international study involving 60 patients to evaluate istaroxime's efficacy. Following positive phase 2 trials, Windtree plans further phase 2b trials to optimize therapy for specific patient populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.47%
Tags
none
-
Rhea-AI Summary

Windtree Therapeutics reported a net loss of $32.6 million for 2020, with an operating loss of $30.3 million. In Q4 2020, the company had a net loss of $7.5 million, reflecting increased expenses in R&D and G&A. The company completed a $30 million equity financing in Q1 2021, netting approximately $27.3 million to fund ongoing clinical trials for istaroxime and KL4 surfactant. The company also announced a new patent for its AEROSURF device, extending protection until 2039. Cash and equivalents stood at $16.9 million at year-end 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.55%
Tags
-
Rhea-AI Summary

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has closed a public offering of 9,230,500 shares of common stock at $3.25 per share, generating gross proceeds of approximately $30 million. The offering included warrants to purchase an equal number of shares at an exercise price of $3.60. Proceeds will fund the advancement of the lead product istaroxime for acute heart failure and continue developing other pipeline candidates. Oppenheimer & Co. and Ladenburg Thalmann acted as managers for the offering, which was conducted under a previously effective shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.86%
Tags
Rhea-AI Summary

Windtree Therapeutics (WINT) announced the pricing of a public offering of 9,230,500 shares of common stock at $3.25 each, including warrants to purchase the same number of shares. The offering aims to raise approximately $30 million in gross proceeds, set to close on March 25, 2021. Funds will be allocated for advancing istaroxime, a new treatment for acute heart failure, and other pipeline candidates, alongside general corporate expenses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.29%
Tags
-
Rhea-AI Summary

Windtree Therapeutics, Inc. (NasdaqCM: WINT) has initiated an underwritten public offering of its common stock and warrants, intended to finance the advancement of its lead product, istaroxime, for acute heart failure, alongside other pipeline candidates. The offering is contingent on market conditions, with no guarantee on its completion or terms. Proceeds will also support a second phase 2b clinical trial and general corporate purposes. Oppenheimer & Co. Inc. and Ladenburg Thalmann & Co. Inc. are managing the offering, filed under Windtree's shelf registration statement.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.29%
Tags
-
Rhea-AI Summary

Windtree Therapeutics (NasdaqCM: WINT) announced an extension of its collaboration with the University of Milan-Bicocca to develop new SERCA2a compounds aimed at treating chronic and acute heart failure. Over the next year, the focus will be on characterizing SERCA2a activators and their interactions with related proteins. This collaboration bolsters Windtree's SERCA2a program, which includes istaroxime, a dual-action agent currently in a Phase 2 study for acute decompensated heart failure and granted Fast Track designation by the FDA based on positive trial results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
Rhea-AI Summary

Windtree Therapeutics, Inc. (NasdaqCM: WINT) announced that CEO Craig Fraser will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2021, at 10:40 AM ET. A live audio webcast will be available on Windtree's website, with a replay accessible for 30 days. Windtree is focused on developing therapies for acute cardiovascular and pulmonary disorders, including its lead candidate istaroxime for heart failure and AEROSURF® for respiratory distress in infants. For more details, visit www.windtreetx.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.01%
Tags
conferences

FAQ

What is the current stock price of Windtree Therapeutics (WINT)?

The current stock price of Windtree Therapeutics (WINT) is $0.3038 as of December 24, 2024.

What is the market cap of Windtree Therapeutics (WINT)?

The market cap of Windtree Therapeutics (WINT) is approximately 2.7M.

What is Windtree Therapeutics' primary focus?

Windtree Therapeutics focuses on developing innovative therapies for critical cardiovascular and respiratory conditions.

What is the KL4 surfactant technology?

KL4 surfactant technology is a synthetic, peptide-containing surfactant structurally similar to human pulmonary surfactant, aimed at treating respiratory diseases, including RDS in premature infants.

What is istaroxime?

Istaroxime is a Phase 2 candidate developed by Windtree Therapeutics to treat acute heart failure and cardiogenic shock by improving both systolic and diastolic cardiac functions.

What recent partnership has Windtree Therapeutics engaged in?

Windtree Therapeutics has entered a significant partnership with Lee's Pharmaceutical to develop and commercialize istaroxime in Greater China.

What is rostafuroxin?

Rostafuroxin is a drug candidate targeting hypertension in patients with specific genetic profiles, currently under development by Windtree Therapeutics.

How has Windtree Therapeutics strengthened its financial position?

Windtree has strengthened its financial position through strategic licensing agreements and partnerships, such as retiring a $15 million liability with Deerfield Management.

What are SERCA2a activators?

SERCA2a activators are compounds developed by Windtree that enhance cardiac function and are being explored for both intravenous and oral treatments for heart failure.

What is the potential market impact of istaroxime?

If approved, istaroxime could become a standard treatment for improving blood pressure and heart function in patients with acute heart failure and cardiogenic shock.

What is Windtree's approach to oncology?

Windtree is developing a preclinical atypical protein kinase C iota (aPKCi) inhibitor for potential applications in rare and broad oncology indications.

Where can I find more detailed financial information about Windtree Therapeutics?

Detailed financial information can be found in Windtree's Annual Report on Form 10-K and other filings available at www.sec.gov.

Windtree Therapeutics, Inc.

Nasdaq:WINT

WINT Rankings

WINT Stock Data

2.73M
8.96M
0.27%
2.06%
0.35%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WARRINGTON